Opthea Limited (NASDAQ:OPT – Free Report) – Analysts at HC Wainwright issued their FY2029 EPS estimates for Opthea in a research note issued on Tuesday, September 3rd. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of $0.50 for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Opthea’s current full-year earnings is ($2.03) per share.
Opthea Stock Performance
NASDAQ:OPT opened at $2.89 on Thursday. The firm has a fifty day simple moving average of $2.33 and a two-hundred day simple moving average of $2.93. Opthea has a 12 month low of $1.60 and a 12 month high of $4.40.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Articles
- Five stocks we like better than Opthea
- How Technical Indicators Can Help You Find Oversold Stocks
- Top 3 Emerging Market ETFs to Watch as the U.S. Dollar Weakens
- Investing In Automotive Stocks
- As Home Prices Hit Highs, These Apartment REITs Offer Growth
- When to Sell a Stock for Profit or Loss
- 3 ETFs to Build a Simple and Balanced Stock Portfolio
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
